Renaissance Technologies - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$6,494
-59.8%
143,067
-50.3%
0.01%
-52.2%
Q2 2023$16,157
-27.9%
287,800
-41.9%
0.02%
-23.3%
Q1 2023$22,394
-30.0%
495,103
-37.1%
0.03%
-31.8%
Q4 2022$31,975
-99.9%
786,600
+32.6%
0.04%
-20.0%
Q3 2022$38,772,000
+12.2%
593,300
+4.3%
0.06%
+34.1%
Q2 2022$34,560,000
-21.6%
568,700
-19.0%
0.04%
-21.2%
Q1 2022$44,083,000
+0.5%
702,300
+21.3%
0.05%
-5.5%
Q4 2021$43,865,000
+192.4%
578,842
+370.2%
0.06%
+189.5%
Q1 2021$15,001,000
-36.0%
123,110
-19.6%
0.02%
-24.0%
Q4 2020$23,456,000
-28.9%
153,200
-61.2%
0.02%
-24.2%
Q3 2020$33,013,000
+21.9%
394,700
+7.1%
0.03%
+43.5%
Q2 2020$27,093,000
+25.5%
368,658
-27.6%
0.02%
+9.5%
Q1 2020$21,594,000
-10.1%
509,175
+29.0%
0.02%
+16.7%
Q4 2019$24,031,000
+1391.7%
394,564
+904.0%
0.02%
+1700.0%
Q3 2019$1,611,000
+394.2%
39,300
+244.7%
0.00%
Q4 2018$326,000
-96.8%
11,400
-93.3%
0.00%
-100.0%
Q2 2018$10,054,000171,1000.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2020
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders